-
A Treatment That Came Just in Time
Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.
by Laurie Adami
-
More Data on COVID-19 Vaccination and Cancer
Studies indicate that many people with cancer have an antibody response to the vaccines, but this response may be reduced or absent in certain patients.
by Anna Goshua
-
Building COVID-19 Vaccine Confidence
Experts discussed how the cancer community can share accurate information and increase confidence in COVID-19 vaccines, both among people with cancer and the general population.
by Kevin McLaughlin
-
Searching the Blood for Signs of Altered Immunity
The immune systems of people with blood cancer respond differently to infection with the coronavirus than the immune systems of people without cancer or with solid tumors.
by Kate Yandell
-
A Drive for Diversity
African Americans are underrepresented in the Be The Match bone marrow donor registry. Patient advocates are working to change that.
by Jon Kelvey
-
Cancer and COVID-19 Vaccination
Amid continued research showing the impact of COVID-19 on people with cancer, patients are asking when they should get a COVID-19 vaccine.
by Marci A. Landsmann
-
Despite Generic Imatinib, Cost of Treating CML Remains High
The arrival of generic versions of the targeted therapy imatinib only modestly reduced the cost of treating chronic myelogenous leukemia patients, a study finds.
by Anna Azvolinsky
Cancer Talk
Declining Breast Cancer Mortality in Younger Women
U.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin
Missed Activities Due to Cancer-related Fatigue and DepressionWomen were more likely than men to have fatigue or depression linked to cancer, and both effects were linked to people withdrawing from physical activities.
by Eric Fitzsimmons
Immunotherapy Improves Results in Head and Neck CancerCombining an immune checkpoint inhibitor with standard care extended event-free survival by nearly two years.
by Thomas Celona
Federal Support for Cancer Research Takes the Stage at AACR Annual MeetingScientists and former administrators gather for session focused on advocating for cancer research in uncertain times.
by Kevin McLaughlin